MedTrace Logo

Study on the Applicability of CCR Criteria in Rectal Cancer

NCT06794099 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 177

Last updated 2025-01-27

No results posted yet for this study

Summary

This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method. The new method combines chemotherapy, radiation, and immune-boosting drugs before surgery. We know these usual ways work for the standard treatment, but we're not sure if they're good enough for this new combo treatment. We'll look at patients with a specific type of rectal cancer that doesn't respond well to just immune-boosting drugs alone. By comparing how patients treated with the new method and the old method respond, we hope to find better ways to tell if the treatment is really working, which could help improve treatment plans for these patients.

Conditions

  • PMMR/MSS Adenocarcinoma of the Colon or Rectum
  • Neoadjuvant Chemoradiotherapy
  • Immunotherapy
  • Complete Response

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2024-10-01
Completion
2025-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794099 on ClinicalTrials.gov